Paper: Reduce Failure and Achieve Meaningful Results in Cardiovascular Devices Prior to Prototype

With more than 30% of all deaths attributed to cardiovascular disease, the healthcare industry invests massively in disease prevention, treatment, and efforts to shorten the recovery period. But the extensive in vitro and in vivo testing required to ensure patient safety inevitably slows down cardiovascular device innovation.

Member Login

Welcome to Revolution in Simulation, an online community. A one-time registration is needed to provide you with free unrestricted access to all Rev-Sim content and to the quarterly newsletter featuring the latest updates, news, events and more.

Not a Registered Member yet? Register once for a RevSim membership